{"id":2508,"date":"2026-11-09T10:51:18","date_gmt":"2026-11-09T09:51:18","guid":{"rendered":"https:\/\/leyton.com\/se\/?post_type=article&p=2508"},"modified":"2026-11-09T11:05:44","modified_gmt":"2026-11-09T10:05:44","slug":"swedish-life-sciences-sector-seeks-capital-and-the-rd-tax-credit-could-return-some-of-it","status":"publish","type":"article","link":"https:\/\/leyton.com\/se\/en\/insights\/articles\/swedish-life-sciences-sector-seeks-capital-and-the-rd-tax-credit-could-return-some-of-it\/","title":{"rendered":"Swedish life sciences sector seeks capital \u2013 and the R&D tax credit could return some of it"},"content":{"rendered":"\n

On paper, the Swedish life sciences sector is thriving. The sector had a turnover of 508 billion kronor in 2023 and accounts for almost 10 per cent of Sweden\u2019s exports of manufactured goods, making it the country\u2019s second-largest export sector\u00b9. But the figures mask a different reality. For most companies, day-to-day life revolves around finding the money for the next step, and that hunt is taking up an increasing proportion of their time and resources.<\/p>\n\n\n\n

Two new reports from SwedenBIO, the Life Science Barometer 2026\u00b9 and the Pipeline Report 2026\u00b2, show both the scale of the potential and how much of it risks being held back by funding issues.<\/p>\n\n\n\n

A pipeline on a par with big pharma, driven by small companies<\/strong><\/h2>\n\n\n\n

According to the Pipeline Report, 152 Swedish companies are collectively driving 518 drug development projects\u00b2. In the preclinical stage, Sweden has more than twice as many assets as pharmaceutical giants such as Roche and AstraZeneca\u00b2.<\/p>\n\n\n\n

This is achieved with limited resources. The entire pipeline is driven by 3,663 employees, and 73 per cent of the companies have fewer than ten employees\u00b2. An equal proportion, 73 per cent, have an annual turnover of less than 10 million kronor\u00b2. It is an industry brimming with ideas but with slim margins.<\/p>\n\n\n\n

The hunt for funding requires ever more resources<\/strong><\/h2>\n\n\n\n

SwedenBIO asked 203 life science leaders what they would like decision-makers to prioritise. Funding came top with 101 mentions, with calls for stronger funding structures, more early-stage capital and long-term stability\u00b9. At the same time, companies are planning to allocate more of their resources to fundraising. On average, they expect to allocate 14 per cent of their resources to funding in the short term and 18 per cent in the longer term, up from 10 per cent and 13 per cent respectively the previous year\u00b9.<\/p>\n\n\n\n

Public funding is crucial for younger companies. Among the companies that took part in the survey, 31 per cent stated that they had received government grants, most of them being younger companies\u00b9.<\/p>\n\n\n\n

The consequences are evident in the pipeline. The report highlights persistent difficulties in taking projects from Phase II to Phase III and attributes this largely to insufficient funding\u00b2. Since 2022, 17 companies have gone into administration or been wound up\u00b2.<\/p>\n\n\n\n

Research is carried out here, and companies want to recruit<\/strong><\/h2>\n\n\n\n

Despite the challenging capital climate, research remains closely linked to Sweden. Ongoing research projects are the most common value-creating asset for companies in the domestic market. 55 per cent of respondents have research projects that create value in Sweden\u00b9.<\/p>\n\n\n\n

Confidence in the future is also strong. 58 per cent of the companies plan to increase their workforce in 2026. Only seven companies, 4 per cent, expect to reduce their workforce\u00b9. This makes payroll costs for R&D staff one of the largest and most important items to optimise.<\/p>\n\n\n\n

The R&D tax credit: capital already within the business<\/strong><\/h2>\n\n\n\n

This is an opportunity that many companies do not fully utilise. The Swedish R&D tax credit reduces employer\u2019s contributions and the general payroll tax for staff working in research and development. The reduction amounts to 20 per cent of the contribution base, which corresponds to almost two-thirds of the employer\u2019s social security contributions for these employees. The ceiling is 3 million kronor per month per group. The deduction applies regardless of whether the company is making a profit or not, which makes it particularly valuable for companies that do not yet have any revenue.<\/p>\n\n\n\n

For a company planning to hire more researchers, the savings could fund an additional post, extend the runway by a couple of months, or prevent a project from being put on hold whilst awaiting the next round of funding. Yet many companies miss out on all or part of the deduction. This is rarely because the research is lacking. It is because the documentation and internal procedures are inadequate when the Swedish Tax Agency reviews the application.<\/p>\n\n\n\n

How Leyton can help<\/strong><\/h2>\n\n\n\n

Leyton specialises in helping pharmaceutical and biotechnology companies realise the full value of their R&D investments. We know that time is the scarcest resource in a small company, particularly when a growing proportion is already taken up by fundraising. That is why we take care of the process, so that your researchers can focus on their research.<\/p>\n\n\n\n

Specifically, we help you with the following:<\/p>\n\n\n\n